Polysulfated glycosides and salts thereof
The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.
1. A method for reducing, alleviating, or inhibiting the development of, or reversing the symptoms of, an acute or chronic inflammatory disorder of the airways of mammals, comprising administering to a mammal having said disorder in need of such treatment a therapeutically effective amount of a potassium salt of the compound of formula (I),
wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 independently of each other, is C 1-4 alkyl, —SO 3 H, polysulfated glycosyl or polysulfated diglycosyl group, or a stereoisomer thereof, with the proviso that at least one of R 1 -R 6 is a polysulfated glycosyl or polysulfated diglycosyl group.
2. The method of claim 1 , wherein the inflammatory disorder of the airways is selected from the group consisting of asthma, allergic rhinitis, intrinsic or extrinsic asthma bronciale, acute or chronic bronchitis, chronic obstructive lung disease, and pulmonary fibrosis.
3. The method of claim 2 , wherein the inflammatory disorder of the airways is asthma.
4. The method of claim 1 , wherein the inflammatory disorder of the airways is an asthma-related pathology selected from the group consisting of bronchitis, emphysema, cystic fibrosis, and respiratory distress.
5. The method of claim 1 , wherein the inflammatory disorder of the airways is selected from the group consisting of idiopathic pulmonary fibrosis and autoimmune lung disease.
6. The method of claim 1 , comprising administering the salt as a single or multiple dose.
7. A method for reducing, alleviating, or inhibiting the development of, or reversing the symptoms of, an acute or chronic inflammatory disorder of the airways of mammals, comprising administering to a mammal having said disorder in need of such treatment a therapeutically effective amount of a compound of formula (I),
wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 independently of each other, is C 1-4 alkyl, —SO 3 H, polysulfated glycosyl or polysulfated diglycosyl group, or a pharmaceutically acceptable salt or stereoisomer thereof, with the proviso that at least one of R 1 -R 6 is a polysulfated glycosyl or polysulfated diglycosyl group.
8. The method of claim 7 , wherein said inflammatory disorder of the airways is selected from the group consisting of asthma, allergic rhinitis, intrinsic or extrinsic asthma bronciale, acute or chronic bronchitis, chronic obstructive lung disease, and pulmonary fibrosis.
9. The method of claim 7 , wherein said inflammatory disorder of the airways is an asthma-related pathology selected from the group consisting of bronchitis, emphysema, cystic fibrosis, and respiratory distress.
10. The method of claim 8 , wherein said inflammatory disorder of the airways is asthma.
11. The method of claim 9 , wherein said inflammatory disorder of the airways is selected from the group consisting of idiopathic pulmonary fibrosis and autoimmune lung disease.
12. The method of claim 7 , comprising administering the compound as a single or multiple dose.
13. The method of claim 1 , wherein the salt is 1,2,3,5,6-penta-O-sulfato-4-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-glucitol nona potassium salt.
14. The method of claim 1 , wherein the potassium salt of the compound of formula (I) is selected from the group consisting of:
2,3,4,5,6-penta-O-sulfato-1-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-mannitol nona potassium salt,
1,2,3,4,5-penta-O-sulfato-6-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-glucitol nona potassium salt,
2,3,4,5,6-penta-O-sulfato-1-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-glucitol nona potassium salt,
1,2,4,5,6-penta-O-sulfato-3-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-glucitol nona potassium salt,
1,2,3,5,6-penta-O-sulfato-4-O-(2,3,4,6-tetra-O-sulfato-α-D-glucopyranosyl)-D-glucitol nona potassium salt,
1,2,3,5,6-penta-O-sulfato-4-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-glucitol nona potassium salt,
1,2,3,5,6-penta-O-sulfato-4-O-(2,3,4,6-tetra-O-sulfato-β-D-galactopyranosyl)-D-glucitol nona potassium salt,
2,4,5,6-tetra-O-sulfato-I,3-bis-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-glucitol dodeca potassium salt,
2,4,5,6-tetra-O-sulfato-1,6-bis-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-mannitol dodeca potassium salt,
2,4,5,6-tetra-O-sulfato-1,6-bis-O-(2,3,4,2′,3′,4′,6′-hepta-O-sulfato-β-gentiobiopyranosyl) -D-mannitol octadeca potassium salt,
2,3,4,5,6-penta-O-sulfato-1-O-(2,3,4,2′,3′,4′,6′-hepta-O-sulfato-β-gentiobiopyranosyl)-D-mannitol dodeca potassium salt,
3,4-di-O-methyl-2,5,6-tri-O-sulfato-I-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-D-mannitol hepta potassium salt,
3,4-di-O-methyl-2,5-di-O-sulfato-1,6-bis-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl) -D-mannitol deca potassium salt,
3,4-di-O-methyl-2,5,6-tri-O-sulfato-1-O-(2,3,4,2′,3′,4′,6′-hepta-O-sulfato-β-gentiobiopyranosyl)-D-mannitol deca potassium salt,
3,4-di-O-methyl-2,5-di-O-sulfato-1,6-bis-O-(2,3,6,2′,3′,4′,6′-hepta-O-sulfato-β-lactosyl)-D-mannitol hexadeca potassium salt,
2,3,4,5,6-penta-O-sulfato-1-O-(2,3,4-tri-O-sulfato-α-D-arabinopyranosyl)-D-mannitolocta potassium salt,
2,3,4,5,6-penta-O-sulfato-1-O-(2,3,4-tri-O-sulfato-β-D-xylopyranosyl)-D-mannitol octa potassium salt, and
2,4,5,6-tetra-O-sulfato-1,6-bis-O-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyl)-galactitol dodeca potassium salt.
15. The method of claim 1 or 7 , wherein in the compound of formula (I), R 1 is a polysulfated glycosyl or diglycosyl group and R 2 -R 6 represent —SO 3 H groups; or wherein R 1 , R 2 , R 4 , R 5 and R 6 is —SO 3 H groups and R 3 represents a polysulfated glycosyl or diglycosyl group; or wherein R 1 , R 2 , R 3 , R 5 and R 6 is —SO 3 H groups and R 4 represents a polysulfated glycosyl or diglycosyl group; or wherein R 1 and R 3 is polysulfated glycosyl groups and R 2 , R 4 , R 5 and R 6 represent 13 SO 3 H groups; or wherein R 1 and R 6 is polysulfated glycosyl or diglycosyl group and R 2 , R 3 , R 4 and R 5 represent —SO 3 H groups; or wherein R 1 is a polysulfated glycosyl or diglycosyl group, R 3 and R 4 represent C 1-4 alkyl groups and R 2 , R 5 and R 6 are —SO 3 H groups; or wherein R 1 and R 6 is polysulfated glycosyl or diglycosyl group, R 3 and R 4 represent C 1-4 alkyl groups and R 2 and R 5 are —SO 3 H groups.
16. The method of claim 1 or 7 , wherein in the compound of formula (I), R 1 is a polysulfated glycosyl or diglycosyl group and R 2 -R 6 represent —SO 3 H groups; or wherein R 1 , R 2 , R 4 , R 5 and R 6 is —SO 3 H groups and R 3 represents a polysulfated glycosyl or diglycosyl group; or wherein R 1 , R 2 , R 3 , R 5 and R 6 is —SO 3 H groups and R 4 represents a polysulfated glycosyl or diglycosyl group; or wherein R 1 and R 3 is polysulfated glycosyl groups and R 2 , R 4 , R 5 and R 6 represent —SO 3 H groups; or wherein R 1 and R 6 is polysulfated glycosyl or diglycosyl group and R 2 , R 3 , R 4 and R 5 represent —SO 3 H groups.
17. The method of claim 1 or 7 , wherein the mammal is a human.